SCHEMBL4606466

SCHEMBL4606466

CN(CCCCN1C(=O)c2ccccc2C1=O)Cc1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
MAOB P27338 6/20 1.00
ACHE P22303 11/20 0.97
BCHE P06276 2/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL9373012 0.99 ACHE (0.97) MAOBACHEBCHE
SCHEMBL14030727 0.95 MAOB (1.00) MAOBACHEBCHE
SCHEMBL10951154 0.89 MAOB (1.00) MAOBACHEBCHE
SCHEMBL2399729 0.88 MAOB (0.77) MAOBACHE
Hydrochloric Acid SCHEMBL9374826 0.86 ACHE (0.76) MAOBACHEBCHE
SCHEMBL2400817 0.86 MAOB (0.75) MAOBACHE
SCHEMBL8398570 0.85 MAOB (0.84) MAOBACHEBCHE
Hydrochloric Acid SCHEMBL9370339 0.84 ACHE (0.72) MAOBACHE
SCHEMBL10462357 0.83 MAOB (0.70) MAOBACHE
SCHEMBL13590254 0.83 ACHE (0.73) MAOBACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3154934-B1 COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES UNIV LILLE (FR) 2021-04-14 EP disclosed
US-20210040034-A1 COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES UNIV LILLE II DROIT & SANTE (FR) 2021-02-11 US disclosed
US-10844008-B2 Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases UNIVERSITE DE LILLE 2 DROIT ET SANTE (FR) 2020-11-24 US disclosed
US-20190092721-A1 COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES UNIVERSITE DE LILLE 2 DROIT ET SANTE (FR) 2019-03-28 US disclosed
US-10179761-B2 Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases UNIVERSITE DE LILLE 2 DROIT ET SANTE (FR) 2019-01-15 US disclosed
US-20170107174-A1 COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES UNIVERSITE DE LILLE (FR) 2017-04-20 US disclosed
EP-3154934-A1 COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES Université de Lille 2 Droit et Santé (FR) 2017-04-19 EP disclosed
WO-2015193255-A1 COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES UNIVERSITE DE LILLE 2 DROIT ET SANTE (FR) 2015-12-23 WO disclosed
US-20080306067-A1 Modulators of Chemokine Receptor Activity WEIGAND KLAUS 2008-12-11 US disclosed
EP-1943235-A1 ARYLUREA DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY Novartis AG (CH) 2008-07-16 EP disclosed
WO-2007048771-A1 ARYLUREA DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY NOVARTIS AG (CH) 2007-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306067-A1 Modulators of Chemokine Receptor Activity CCR3, CCR1, CCR4 MAOB 3325/4885ACHE 4165/4885BCHE 3046/4885
US-20210040034-A1 COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES MAPT, PSEN2, SNCA MAOB 97/4885ACHE 15/4885BCHE 29/4885
US-10844008-B2 Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases MAPT, PSEN2, SNCA MAOB 97/4885ACHE 15/4885BCHE 29/4885
US-20170107174-A1 COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES MAPT, PSEN2, SNCA MAOB 97/4885ACHE 15/4885BCHE 29/4885
US-20190092721-A1 COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES MAPT, PSEN2, SNCA MAOB 97/4885ACHE 15/4885BCHE 29/4885
US-10179761-B2 Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases MAPT, PSEN2, SNCA MAOB 97/4885ACHE 15/4885BCHE 29/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.